Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indications,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.”
Read the full article: Biogen Completes Acquisition of Human Immunology Biosciences //
Source: https://www.globenewswire.com/news-release/2024/07/02/2907482/0/en/Biogen-Completes-Acquisition-of-Human-Immunology-Biosciences.html